We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-2.94%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.56B
AUM Growth
-$105M
Cap. Flow
+$128M
Cap. Flow %
4.99%
Top 10 Hldgs %
48.1%
Holding
79
New
9
Increased
20
Reduced
11
Closed
4

Top Buys

Rank Stock Value
1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$66.5M
2
AMRN
Amarin Corp
AMRN
+$47.6M
3
WHWK
Whitehawk Therapeutics
WHWK
+$35M
4
TYRA icon
Tyra Biosciences
TYRA
+$32.4M
5
KYMR icon
Kymera Therapeutics
KYMR
+$31.9M

Top Sells

Rank Stock Value
1
MRUS
Merus
MRUS
+$156M
2
ARGX icon
argenx
ARGX
+$90.3M
3
RLAY icon
Relay Therapeutics
RLAY
+$29.9M
4
FBRX icon
Forte Biosciences
FBRX
+$19.9M
5
IMVT icon
Immunovant
IMVT
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 94.03%
2 Financials 0.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GHRS icon
1
GH Research
GHRS
$1.95B
$205M 7.98%
9,275,158
+2
+0% +$41
KYMR icon
2
Kymera Therapeutics
KYMR
$8.6B
$187M 7.29%
3,180,658
+550,000
+21% +$31.9M
OLMA icon
3
Olema Pharmaceuticals
OLMA
$1.02B
$184M 7.16%
6,661,503
– –
RCUS icon
4
Arcus Biosciences
RCUS
$3.5B
$113M 4.39%
3,229,822
+432,000
+15% +$13.4M
MRUS
5
CALL
DELISTED
Merus
MRUS
$111M 4.34%
+5,060,071
New +$109M
ARGX icon
6
argenx
ARGX
$53.9B
$111M 4.31%
366,204
-285,000
-44% -$90.3M
RPTX
7
DELISTED
Repare Therapeutics
RPTX
$97.7M 3.81%
3,722,398
– –
XOMA
8
DELISTED
Xoma
XOMA
$87.4M 3.41%
3,530,543
– –
PTGX icon
9
Protagonist Therapeutics
PTGX
$8.7B
$69.1M 2.7%
3,901,759
+147,664
+4% +$6.3M
LXRX icon
10
Lexicon Pharmaceuticals
LXRX
$1.02B
$69.1M 2.69%
14,360,000
+5,966,000
+71% +$24.5M
RVMD icon
11
Revolution Medicines
RVMD
$39.9B
$68.4M 2.67%
2,485,049
– –
RLAY icon
12
Relay Therapeutics
RLAY
$4.12B
$64.6M 2.52%
2,049,113
-889,089
-30% -$29.9M
LKFT
13
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.79B
$58.9M 2.3%
+1,119,733
New +$66.5M
AMRN
14
Amarin Corp
AMRN
$297M
$58.2M 2.27%
570,359
+484,560
+565% +$47.6M
FDMT icon
15
4D Molecular Therapeutics
FDMT
$539M
$54.1M 2.11%
2,005,862
– –
SNDX icon
16
Syndax Pharmaceuticals
SNDX
$1.69B
$47.5M 1.85%
2,486,429
– –
ACIU icon
17
AC Immune
ACIU
$226M
$46.5M 1.82%
6,935,179
-1,610,000
-19% -$11.5M
VSTM icon
18
Verastem
VSTM
$503M
$46.1M 1.8%
1,248,105
+307,583
+33% +$11.3M
RAIN
19
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$44.2M 1.73%
2,957,807
+1,011,858
+52% +$17.3M
WHWK
20
Whitehawk Therapeutics
WHWK
$191M
$33.7M 1.31%
+1,147,052
New +$35M
SPRO icon
21
Spero Therapeutics
SPRO
$68.9M
$33.3M 1.3%
1,809,352
-328,626
-15% -$5.27M
KURA icon
22
Kura Oncology
KURA
$805M
$30.6M 1.19%
1,635,112
– –
TYRA icon
23
Tyra Biosciences
TYRA
$1.92B
$29.8M 1.16%
+1,694,933
New +$32.4M
INFI
24
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$28.7M 1.12%
8,383,645
– –
PVLA
25
Palvella Therapeutics
PVLA
$2.05B
$27.5M 1.07%
66,603
– –
1
2 3 4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q3 2021 Portfolio in Review

As of Q3 2021, BVF Inc held 79 positions worth $2.56B, down 3.9% from $2.67B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

BVF Inc deployed $128M of net new capital in Q3 2021, opening 9 new positions and adding to 20 existing holdings. Its largest new stake was Lakefront Biotherapeutics American Depositary Shares: 1,119,733 shares worth $58.9M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 98% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was argenx, an estimated $90.3M trimmed.

  • BVF Inc's largest Q3 2021 buy was Lakefront Biotherapeutics American Depositary Shares: 1,119,733 shares worth $58.9M.
  • BVF Inc added most to Amarin Corp in Q3 2021, an estimated $47.6M increase.
  • BVF Inc's biggest Q3 2021 reduction was argenx, cutting an estimated $90.3M.
  • BVF Inc fully exited Merus in Q3 2021, selling an estimated $156M.
  • BVF Inc's ten largest holdings make up 48% of its $2.56B portfolio in Q3 2021.
  • BVF Inc opened 9 new positions and closed 4 in Q3 2021.
  • BVF Inc's portfolio value fell 3.9% quarter-over-quarter to $2.56B.

Based on BVF Inc's 13F filing for Q3 2021, filed 15 Nov 2021.